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different than expected with standard RCHOP. Results from additional
patients will be presented at the ICML meeting.
Keywords: diffuse large B‐cell lymphoma (DLBCL); lenalidomide;
obinutuzumab.
279
ONGOING PHASE 1/2 STUDY OF
INCB050465, A SELECTIVE PI3Kδ
INHIBITOR, FOR THE TREATMENT OF
PATIENTS (PTS) WITH RELAPSED/
REFRACTORY (R/R) B‐CELL MALIGNANCIES
(CITADEL‐101)
P. Caimi1* | R. Ramchandren2 | T.J. Phillips3 | M.S. Wertheim4 |
M.E. Gutierrez5 | W.J. Edenfield6 | L.P. Akard7 | J.A. Call8 |
D.O. Persky9 | D.J. DeMarini10 | L. Zhou10 | S. Yeleswaram10 |
A. Forero‐Torres11
1Department of Medicine‐Gastroenterology, University Hospitals Seidman
Cancer Center, Cleveland, OH, USA; 2Hematology/Oncology, Karmanos
Cancer Center, Detroit, MI, USA; 3Hematology/Oncology, University of
Michigan, Ann Arbor, MI, USA; 4Hematology/Oncology, Hematology/
Oncology Associates of Treasure Coast, Port St Lucie, FL, USA; 5Drug
Discovery and Phase I Unit, Hackensack University Medical Center,
Hackensack, NJ, USA; 6Hematology, Greenville Health System Cancer
Institute, Greenville, SC, USA; 7Hematology, Indiana Blood & Marrow
Transplantation, LLC, Indianapolis, IN, USA; 8Hematology/Oncology, Utah
Cancer Specialists‐Network, Salt Lake City, UT, USA; 9Hematology/
Oncology, University of Arizona Cancer Center, Tucson, AZ, USA;
10Clinical Development, Incyte Corporation, Wilmington, USA;
11Hematology/Oncology, University of Alabama Birmingham,
Birmingham, AL, USA
Introduction: INCB050465 is a potent, selective PI3Kδ inhibitor
(≥19,000‐fold selectivity for PI3Kδ vs other isoforms), which has dem-
onstrated linear pharmacokinetics (PK) and achieved exposure levels
several‐fold greater than the IC90 for PI3Kδ inhibition at the recom-
mended phase 2 dose (ASH 2016; Abstract 4195). Here, we report
emerging safety and efficacy results from pts receiving INCB050465
monotherapy for r/r B‐cell malignancies in an ongoing phase 1/2 study
(NCT02018861).
Methods: Eligible pts (≥18 y) had ECOG PS ≤2 (≤1 during dose escala-
tion), normal liver and kidney function, and no autologous HSCT within
3 months or allogeneic HSCT within 6 months of screening. The proto-
col was initiated with a single‐pt cohort, treated with oral INCB050465
5 mg QD. Subsequent cohorts used a 3 + 3 design and evaluated doses
of 10–45 mg QD. Based on PK/PD, the 20 and 30 mg QD cohorts
were expanded. Responses were assessed Q9W using Lugano Classifi-
cation or International Working Group on Chronic Lymphocytic Lym-
phoma (CLL) criteria.
Results: As of the data cut‐off (Nov 1, 2016), 52 pts were treated
(median age, 65 y [range, 30–88]; disease subtypes: diffuse large B‐cell
lymphoma [DLBCL; n = 14], follicular lymphoma [FL; n = 10], Hodgkin
lymphoma [HL; n = 9], marginal zone lymphoma [MZL; n = 8], CLL
[n = 6], mantle cell lymphoma [MCL; n = 5]). Approximately 62% of
pts had ≥3 prior systemic regimens; 31% had prior HSCT. Median
duration of therapy was 3.3 months (range, 0.6–13.4); no DLTs were
identified. Approximately 67% of pts discontinued therapy, most com-
monly for disease progression (31%) and AEs (25%). Approximately
33% of pts had dose interruption; 4% had reduction. Most common
nonhematologic AEs (all grade [Gr]; Gr ≥3) were nausea (38%; 0%),
diarrhea (31%; 6%), and vomiting (25%; 0%). Gr ≥3 hematologic AEs
included neutropenia (21%), lymphopenia (17%), thrombocytopenia
(10%), and anemia (4%). Approximately 40% of pts had serious AEs,
most frequently colitis, diarrhea, and hypotension (all n = 3). A total
of 1 pt had Gr 3 pneumonitis; none had Pneumocystis
jiroveciipneumonia (PJP) or Gr ≥2 elevated transaminase. Objective
responses (OR) occurred at all doses (Table), except 5 mg QD; 90%
of the ORs were observed at the 9‐week disease assessment.
Conclusion: INCB050465 demonstrated manageable toxicities with no
clinically meaningful transaminitis or PJP. OR rates were generally high
and most responses (90%) were observed at the 9‐week disease
assessment. Different dosing regimens/schedules, long‐term safety,
and disease‐specific cohorts are being evaluated.
Na
Objective Response,
n (%)
Complete Response,
b n
Partial Response,
b n
NHL 31 19 (61) 10 9
DLBCL 14 5 (36) 3 2
FL 9 7 (78) 2 5
MZL 4 4 (100) 2 2
MCL 4c 3 (75) 3 0
CLL 6c 2 (33) 0 2
HL 8 1 (13) 0 1
a7 pts were not evaluable for response because they had not reached a
postbaseline assessment as of the data cutoff date.
bRadiologic/metabolic.
c1 patient with MCL and 3 with CLL had previously received ibrutinib; among
these 4 pts, 1 objective response (partial response in CLL) was observed in this
study.
Keywords: B‐cell lymphoma; non‐Hodgkin lymphoma (NHL); PI3K/
AKT/mTOR.
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Introduction: Relapsed follicular lymphoma (FL) remains a challenge
and salvage regimens are associated with toxicity and limited control.
Clinical outcomes are linked to dynamic changes in the immune micro-
environment and novel immune‐based approaches such as
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